Biovista, one of the world leaders in drug repositioning, is hosting a lunch and panel discussion on “Drug Repositioning in Rare and Orphan Diseases”, October 18th in Washington DC. Interested parties are invited to register. The discussion will involve thought leaders from associations such as CFIDS, Partnership for Cures and FARA and will explore if … Read More
Author: Vassilis Virvilis
Biovista to host Drug Repositioning Workshop at 2nd World PGX Summit
CHARLOTTESVILLE, Virginia, March 20, 2012 — Biovista announced today that it will be organizing a workshop on drug repositioning at the upcoming World Pharmacogenomics Summit being held April 24-26 in Boston. The Workshop entitled “Understand How to Use PGx in Drug Repositioning, Adverse Event Prediction, Patient Subpopulation Stratification and Personalized Medicine” will help strategic level … Read More
Biovista Awarded Research Grant on Chronic Fatigue Syndrome From Solve ME/CFS Initiative
CHARLOTTESVILLE, Virginia, March 6, 2012 /PRNewswire/ — Biovista announced today that it has been awarded a prestigious research grant by Solve ME/CFS Initiative to identify non-obvious mechanisms of the disease and potential drug repositioning candidates that will advance objective diagnosis and effective treatment of chronic fatigue syndrome (CFS). As part of its work, Biovista will share … Read More
CFIDS grant: Presentation of project members
Breaking Ground Article by K. Kimberly McCleary, about the Research Institute Without Walls. We believe in the power of systematically exploring all drugs and mechanisms for their potential against any disease. We have used this idea as the driving force to create a technologic capability, COSS, that maps and ranks all drugs versus all diseases, side … Read More
Drug Discovery & Development: New Life for Old Drugs
Saving time and money The resources required to bring a new drug to market are as well-known as they are staggering: upwards of $1.3 billion in costs, 10 to 15 years from target selection to approval, and an overall failure rate approaching 95%.